A US cohort study with at least 3 years of follow-up reported that serum PON1 was inversely related to total plasma oxidized fatty acid levels, and was associated with a lower incident risk of major adverse cardiovascular events (MACE), including nonfatal and fatal myocardial infarction, nonfatal and fatal stroke, and all-cause mortality, suggesting an atheroprotective effect of PON1 [34]. Here, PON1 is linked to stroke disorder.